Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guilty: Amgen to pay $762M in latest off-label bust

This article was originally published in Scrip

Executive Summary

Amgen wasn't satisfied with the profits it stood to make on its erythropoiesis-stimulating agent (ESA) Aranesp (darbepoetin alfa), and so it illegally promoted the drug's use to doctors at a higher, less-frequent dosing regimen, said Marshall Miller, the acting US Attorney for the Eastern District of New York in Brooklyn.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019811

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel